Cargando…

Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated

INTRODUCTION: There is a need for new therapies in Parkinson’s disease that may help to address known limitations of current options. PF-06649751 is a novel, highly selective dopamine D1/D5 agonist targeted for Parkinson’s disease treatment. METHODS: The safety, pharmacokinetics, and pharmacodynamic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sohur, U. Shivraj, Gray, David L., Duvvuri, Sridhar, Zhang, Yao, Thayer, Kathleen, Feng, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283789/ https://www.ncbi.nlm.nih.gov/pubmed/30361858 http://dx.doi.org/10.1007/s40120-018-0114-z

Ejemplares similares

PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial
por: Riesenberg, Robert, et al.
Publicado: (2020)

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
por: Isaacson, Stuart H., et al.
Publicado: (2023)

Dopamine D(1) Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease
por: Lewis, Mechelle M., et al.
Publicado: (2023)

Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation
por: Kozak, Rouba, et al.
Publicado: (2020)

Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists
por: Pogorelov, Vladimir M., et al.
Publicado: (2023)

Developmental Controls are Re-Expressed during Induction of Neurogenesis in the Neocortex of Young Adult Mice
por: Sohur, U. Shivraj, et al.
Publicado: (2012)

A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory Capacity
por: Balice-Gordon, Rita, et al.
Publicado: (2020)

Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor
por: Gray, David L., et al.
Publicado: (2018)

Inhibitory Effects of Dopamine Receptor D(1) Agonist on Mammary Tumor and Bone Metastasis
por: Minami, Kazumasa, et al.
Publicado: (2017)

Dopamine receptor D1- and D2-agonists do not spark brown adipose tissue thermogenesis in mice
por: Raffaelli, Francesca-Maria, et al.
Publicado: (2020)

Specificity of striatal dopamine D(1) system in humans: implications for clinical use of D(1) receptor-agonists in Parkinson's disease
por: Goto, Satoshi
Publicado: (2023)

Successful treatment of dopamine dysregulation syndrome with dopamine D(2) partial agonist antipsychotic drug
por: Mizushima, Jin, et al.
Publicado: (2012)

In Vitro and In Silico Characterization of Kurarinone as a Dopamine D(1A) Receptor Antagonist and D(2L) and D(4) Receptor Agonist
por: Prajapati, Ritu, et al.
Publicado: (2021)

Crystal structure of dopamine D1 receptor in complex with G protein and a non-catechol agonist
por: Sun, Bingfa, et al.
Publicado: (2021)

Author Correction: Inhibitory effects of dopamine receptor D(1) agonist on mammary tumor and bone metastasis
por: Minami, Kazumasa, et al.
Publicado: (2022)

Dopamine D1 Receptor in Cancer
por: Sobczuk, Paweł, et al.
Publicado: (2020)

Novel and Potent Dopamine D(2) Receptor Go-Protein Biased Agonists
por: Bonifazi, Alessandro, et al.
Publicado: (2019)

PMON169 D2R Expression in Dopamine-Agonist Resistant Prolactinomas
por: Levine, Alice, et al.
Publicado: (2022)

Infusion of D1 Dopamine Receptor Agonist into Medial Frontal Cortex Disrupts Neural Correlates of Interval Timing
por: Parker, Krystal L., et al.
Publicado: (2015)

T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN
por: Tamagnan, Gilles, et al.
Publicado: (2018)

A pivotal role of FOS-mediated BECN1/Beclin 1 upregulation in dopamine D2 and D3 receptor agonist-induced autophagy activation
por: Wang, Jian-Da, et al.
Publicado: (2015)

Voltage-Dependent Dopamine Potency at D(1)-Like Dopamine Receptors
por: Ågren, Richard, et al.
Publicado: (2020)

Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment
por: Mandic-Maravic, Vanja, et al.
Publicado: (2022)

The Signaling and Pharmacology of the Dopamine D1 Receptor
por: Jones-Tabah, Jace, et al.
Publicado: (2022)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

Agonist signalling properties of radiotracers used for imaging of dopamine D(2/3) receptors
por: van Wieringen, Jan-Peter, et al.
Publicado: (2014)

Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor
por: Adhikari, Pramisha, et al.
Publicado: (2021)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Evidence against dopamine D1/D2 receptor heteromers
por: Frederick, Aliya L., et al.
Publicado: (2015)

Mechanism of dopamine binding and allosteric modulation of the human D1 dopamine receptor
por: Zhuang, Youwen, et al.
Publicado: (2021)

A Novel Dopamine Receptor Signaling Unit in Brain: Heterooligomers of D1 And D2 Dopamine Receptors
por: George, Susan R., et al.
Publicado: (2007)

Chronic exposure to dopamine agonists affects the integrity of striatal D(2) receptors in Parkinson's patients
por: Politis, Marios, et al.
Publicado: (2017)

Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole
por: Kikuchi, Tetsuro, et al.
Publicado: (2021)

Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue
por: Ågren, Richard, et al.
Publicado: (2021)

Conscious perception and the modulatory role of dopamine: no effect of the dopamine D2 agonist cabergoline on visual masking, the attentional blink, and probabilistic discrimination
por: Boonstra, E.A, et al.
Publicado: (2020)

Dopamine and dopamine receptor D1 as a novel favourable biomarker for hepatocellular carcinoma
por: Wang, Zhihui, et al.
Publicado: (2021)

Enhanced Taste Recognition Following Subacute Treatment With The Dopamine D2/D3 Receptor Agonist Pramipexole in Healthy Volunteers
por: Kaltenboeck, Alexander, et al.
Publicado: (2022)

Changes of Locomotor Activity by Dopamine D2, D3 Agonist Quinpirole in Mice Using Home-cage Monitoring System
por: Park, Jeonghyun, et al.
Publicado: (2023)

Investigation of D(1) Receptor–Agonist Interactions and D(1)/D(2) Agonist Selectivity Using a Combination of Pharmacophore and Receptor Homology Modeling
por: Malo, Marcus, et al.
Publicado: (2012)

Dopamine Agonists and Pathologic Behaviors
por: Kelley, Brendan J., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_cbgcof4fq3bsnhcau06h834br8